金吾财讯 | 摩根士丹利发研报指，下调中国中药(00570)2025-2030年盈利预测8-13%，主要原因是配方颗粒业务进一步降价(毛利率下降)及销售额下降。同时考虑额外的减损和补缴税款，这些趋势很可能从2024年开始持续下去。对该公司的目标价和不同情境值下调6-11%。该行将中国中药目标价由1.7港元下调5.9%至1.6港元，维持“减持”评级。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.